2024 SABCS Highlights – Dana-Farber
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
Related Articles
Limertinib Wins Approval in China for EGFR T790M+ NSCLC
Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.
Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma
David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.
LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer
LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Abstract. The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic
Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer
Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
CMG901 showed a manageable safety profile and had promising antitumour activity in patients with advanced gastric or gastro-oesophageal junction cancer.
Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery
Annals of Surgical Oncology – The association of hospital market competition, financial costs, and quality of oncologic care has not been well-defined. This study sought…
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
The assumption that thermal ablation should be reserved for unresectable colorectal liver metastases requires re-evaluation and the preferred treatment should be individualised and based on…
FDA Approves Sotorasib Plus Panitumumab for KRAS G12C–Mutated Colorectal Cancer
The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.
Managing R/R Multiple Myeloma: Current Strategies and Future Directions in Community Practice
The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR…
